공시 • Mar 22
Harpoon Therapeutics Files Form 15 Harpoon Therapeutics, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.0001 per share. 공시 • Jan 09
Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million. Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million on January 7, 2024. Under the terms of the agreement, Merck, will acquire all outstanding shares of Harpoon Therapeutics, Inc. for a price per share of $23 in cash. Upon termination of the agreement under certain specified circumstances, Harpoon Therapeutic would be required to pay Merck a termination fee of $23.86 million.
The board of directors of Harpoon has unanimously approved the transaction. The board of directors of Merck Sharp & Dohme has approved the transaction. The transaction is subject to certain conditions, including approval of the merger by Harpoon’s stockholders, the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and other customary conditions. The transaction is expected to close in the first half of 2024.
Catherine J. Dargan, Andrew M. Fischer and Michael J. Riella of Covington & Burling LLP acted as its legal advisor and Evercore Group L.L.C. acted as financial advisor to Merck. Stuart M. Cable, Lisa R. Haddad, Jean A. Lee, Amanda Gill, Maggie L. Wong, Marianne C. Sarrazin, Alex Apostolopoulos, Arman Oruc, Jacob R. Osborn, Christopher J. Denn, Julie Tibbets, Nathan J. Brodeur, Jacqueline Klosek, Lore Leitner, Robert M. Hale, Alexandra S. Denniston, Andrew C. Sucoff, Matt Wetzel, Deborah S. Birnbach, Alicia Tschirhart, Simone Waterbury, Brian H. Mukherjee and Christina Ademola of Goodwin Procter LLP acted as legal advisor and Centerview Partners LLC acted as financial advisor and fairness opinion provider to Harpoon. Board Change • Jan 08
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. Independent Director Lauren Silvernail was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. 공시 • Dec 26
Harpoon Therapeutics, Inc. Announces Board Changes Harpoon Therapeutics, Inc. announced the appointment of James Bucher, J.D. as Chief Legal Officer, and the promotion of Wendy Chang, to Chief People Officer. Mr. Bucher and Ms. Chang are part of the executive management team and report directly to the Chief Executive Officer. Mr. Bucher is a proven leader with over thirty years of legal expertise, including over ten years dedicated to senior roles in life science companies. Most recently, he served as Executive Vice President, General Counsel, and Head of Human Resources at Eliem Therapeutics. Mr. Bucher also served as Executive Vice President and General Counsel for Alder Biopharmaceuticals, held a senior legal position at Exelixis, consulted life sciences companies, and was a partner at Shearman & Sterling LLP. In his current role at Harpoon, Mr. Bucher is tasked with leading all legal aspects of the organization, including corporate governance, intellectual property, and compliance functions. Mr. Bucher received his J.D. with distinction from Emory University School of Law and his B.A. from Colgate University. Ms. Chang joined Harpoon in 2022 as Senior Vice President of Human Resources, bringing more than twenty years of human resources experience in life sciences. Ms. Chang’s promotion to the role of Chief People Officer demonstrates her valuable contributions to the Company during her tenure, along with the organization's commitment to its employees, corporate culture, and the future growth and development of its team. Ms. Chang has an extensive background in aligning talent with organizations’ overall vision and direction. Before joining Harpoon, she was Head of People and Culture at IDbyDNA; before that, she served as Vice President, Human Resources at Gilead Sciences. Ms. Chang?earned a B.S. in accounting and business/management from the University of California, Riverside, and completed the Global Fellow of Talent Management program at The Wharton School of the University of Pennsylvania. 공시 • Dec 12
Harpoon Therapeutics, Inc. Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH2023 and Announces Selection of Recommended Phase 2 Dose (RP2D) Harpoon Therapeutics, Inc. reported data from the Phase 1 study of HPN217 in patients with RRMM in an oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego. Harpoon also announced the selection of 12 mg as the HPN217 RP2D. During the trial, 97 patients with RRMM who had received at least three prior therapies were enrolled across 15 dose escalation cohorts and three expansion regimens. As of the data cut-off of October 17, 2023, the data demonstrated: Clinical activity across a wide dose range (2.15 mg to 24 mg). The maximum tolerated dose (MTD) was not reached at the target dose using a step up approach. · Optimal activity and safety profile was seen at 12 mg, which was declared the RP2D. The Overall Response Rate (ORR) across 12 mg cohorts was 63% (12/19, 95% CI: 38, 84). In addition, the depth of response was most significant at 12 mg, with 53% (10/19) of patients having a Very Good Partial Response (VGPR) or better. The median time to first response in the 12 mg and 24 mg cohort was 1.2 months, and the median duration of response for all responders was 20.5 months as of the data cutoff date. Out of all the responders, 58% (22/38) remain on treatment. · In the 12 mg and 24 mg cohorts, nine patients were previously exposed to BCMA-targeting agents, and six of those patients responded to the HPN217 treatment. The incidence of cytokine release syndrome (CRS) was lowest (16%) in the 12 mg cohorts, all Grade 1-2. No immune effector cell associated neurotoxicity syndrome (ICANS) events were observed at the 12 mg dose. 